Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yue Shentu

Showing results (21-30 of 21) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 21 results.
Lancet (London, England)|December 30, 2015
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialRoy S Herbst, Paul Baas, Dong-Wan Kim, et al.
Pageof 3

Showing results (21-30 of 21) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 21 results.
Lancet (London, England)|December 30, 2015
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialRoy S Herbst, Paul Baas, Dong-Wan Kim, et al.
Pageof 3